PHARMACOECONOMIC ASPECTS OF PARKINSON’S DISEASE THERAPY
DOI:
https://doi.org/10.11603/1681-2786.2020.2.11411Keywords:
Parkinson’s disease, treatment, pharmacoeconomic analysisAbstract
Purpose: to determine the pharmacoeconomic characteristics of the use of anti-parkinsonian drugs registered in Ukraine.
Materials and Methods. Information on the cost and volume of sales of anti-parkinsonian drugs is obtained from open sources. The average cost of treatment per month was calculated taking into account the recommended maximum and minimum doses. Information on the actual state of prescription of anti-parkinsonian drugs was obtained by retrospective analysis of the appointments of the regional consultative and diagnostic center for extrapyramidal disorders for 2015–2020.
Statistical processing was performed using Statistica 10.0 software (Dell StatSoft Inc., USA)
Results and Discussion. In the analysis of the actual practice of prescribing anti-parkinsonian drugs, it was found that most often patients were prescribed levodopa and pramipexole, while 6.6 % of patients at the time of inclusion in the register did not receive any therapy. 18.4 % of patients were on monotherapy, 15.4 % received two drugs, 8.9 % received three drugs, and 2.5 % of patients received more than 3 drugs at the same time. The most economically available as monotherapy are the use of cholinergic drugs and amantadine. Dopamine agonists and MAO-B inhibitors may be used in younger patients, depending on the prevailing clinical manifestations. Levodopa, including combination drugs, is used in elderly patients and in younger patients with cognitive impairment.
Conclusions. The pharmacoeconomic effect of therapy is higher with early treatment of CP. Monotherapy in the early stages of CP is more cost-effective than the use of drug combinations. The presence of dyskinesia in the late stages of CP increases the direct cost of medical treatment twice.
References
Belousov, D.Yu., & Afanasyeva, Ye.V. (2015). Farmakoekonomicheskiy analiz primeneniya pramipeksola prolongirovannogo deystviya v rezhime monoterapii na rannikh stadiyakh bolezni Parkinsona [Pharmacoeconomic analysis of the use of pramipexole with prolonged action in monotherapy in the early stages of Parkinson’s disease]. Kachestvennaya klinicheskaya praktika – Qualitative Clinical Practice, 1, 53-64 [in Russian].
Belousov, D.Yu., Afanasyeva, Ye.V., & Yefremova, Ye.A. (2013). Farmakoekonomicheskiy analiz primeneniya protivoparkinsonicheskikh preparatov v rezhime monoterapii na rannikh stadiyakh bolezni Parkinsona [Pharmacoeconomic analysis of the use of antiparkinsonian drugs in monotherapy in the early stages of Parkinson’s disease]. Kachestvennaya klinicheskaya praktika – Qualitative Clinical Practice, 1, 27-43 [in Russian].
Levin, O.S., Smolentseva, I.G., & Fedorova, N.V. (2008). Kliniko-farmakoekonomicheskoye issledovaniye effektivnosti “Stalevo” v lechenii bolezni Parkinsona s motornymi flyuktuatsiyami [Clinical and pharmacoeconomic study of the effectiveness of “Stalevo” in the treatment of Parkinson’s disease with motor fluctuations]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova – S.S. Korsakov Journal of Neurology and Psychiatry, 108, 7, 27-34 [in Russian].
Levin, O.S. (2017). Dolgosrochnaya dofaminergicheskaya terapiya bolezni Parkinsona [Long-term dopaminergic therapy of Parkinson’s disease]. Meditsinskiy sovet – Medical Council, 10, 74-80 [in Russian]. DOI: https://doi.org/10.21518/2079-701X-2017-10-74-80
Prohrama “Dostupni liky”. [“Affordable Medicines” program]. Retrieved from: https://moz.gov.ua/dostupni-liki [in Ukrainian].
Rebrova, O.Yu. (2002). Statisticheskiy analiz meditsinskikh dannykh. Primeneniye paketa prikladnykh programm STATISTICA [Statistical analysis of medical data. Application of the STATISTICA application package]. Moscow: MediaSfera [in Russian].
Reyestr hranychnykh optovo-vidpusknykh tsin na deiaki likarski zasoby [Register of marginal wholesale prices for some medicines]. Retrieved from: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-24022020--508-pro-zatverdzhennja-reestru-granichnih-optovo-vidpusknih-cin-na-dejaki-likarski-zasobi-scho-zakupovujutsja-za-bjudzhetni-koshti-stanom-na-03-ljutogo-2020-roku.
Belousov, Yu.B., Chikina, Ye.S., Gekht, A.B., & Belousov, D.Yu. (2006). Rezultaty provedeniya farmakoekonomicheskikh analizov pri lechenii bolezni Parkinsona agonistom dofaminovykh retseptorov mirapeksom [The results of pharmacoeconomic analyzes in the treatment of Parkinson’s disease with the dopamine receptor agonist Mirapex]. Kachestvennaya klinicheskaya praktika – Qualitative Clinical Practice, 2, 38-46 [in Russian].
Rudakova, A.V., & Levin, O.S. (2017). Farmakoekonomicheskiye aspekty kombinirovannogo lecheniya pozdnikh stadiy bolezni Parkinsona [Pharmacoeconomic aspects of combined treatment of late stages of Parkinson’s disease]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova – S.S. Korsakov Journal of Neurology and Psychiatry, 117 (6(2)), 96-100 [in Russian].
Strachunskaya, Ye.Ya., & Abramenkova, I.V. (2006). Intellektualnaya informatsionnaya sistema mnogokriterialnogo analiza farmakoekonomicheskikh i farmakoepidemiologicheskikh pokazateley effektivnosti terapii pri parkinsonizme [Intelligent information system for multicriteria analysis of pharmacoeconomic and pharmacoepidemiological indicators of the effectiveness of therapy in parkinsonism]. Kachestvennaya klinicheskaya praktika – Qualitative Clinical Practice, 2, 47-54 [in Russian].
Cordato, D.J., Schwartz, R., Abbott, E., Saunders, R., & Morfis, L. (2006). A comparison of health-care costs involved in treating people with and without Parkinson’s disease in Southern Sydney, New South Wales, Australia. J. Clin. Neurosci., 13 (6), 655-658. DOI: https://doi.org/10.1016/j.jocn.2005.09.006
Vossius, C., Gjerstad, M., Baas, H., & Larsen, J.P. (2006). Drug costs for patients with Parkinson’s disease in two different European countries. Acta Neurol. Scand., 113 (4), 228-232. DOI: https://doi.org/10.1111/j.1600-0404.2005.00574.x
(2015). Duopa-a carbidopa/levodopa enteral suspension for Parkinson’s disease. Med Lett. Drugs Ther., 57 (1474), 112.
(2018). GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 17 (11), 939-953.
Market cross view. Retrieved from: http://proximaresearch.ua/en/.
Dube, U., Ibanez, L., Budde, J.P., Benitez, B.A., Davis, A.A., Harari, O., ..., & Brown, K.M. (2020). Overlapping genetic architecture between Parkinson disease and melanoma. Acta Neuropathol., 139 (2), 347-364. DOI: https://doi.org/10.1007/s00401-019-02110-z
Martinez-Martín, P., Rodriguez-Blazquez, C., Paz, S., Forjaz, M.J., Frades-Payo, B., Cubo, E., ..., & Lizán, L. (2015). Parkinson symptoms and health related quality of life as predictors of costs: A longitudinal observational study with linear mixed model analysis. PLoS One, 10 (12), e0145310. DOI: https://doi.org/10.1371/journal.pone.0145310
Myall, D.J., Pitcher, T.L., Pearson, J.F., Dalrymple-Alford, J.C., Anderson, T.J., & MacAskill, M.R. (2017). Parkinson’s in the oldest old: Impact on estimates of future disease burden. Parkinsonism Relat. Disord., 42, 78-84. DOI: https://doi.org/10.1016/j.parkreldis.2017.06.018
Racette, B.A., & Willis, A.W. (2015). Time to change the blind men and the elephant approach to Parkinson disease? Neurology, 85 (2), 190-196. DOI: https://doi.org/10.1212/WNL.0000000000001739
Wei, Y.J., Palumbo, F.B., Simoni-Wastila, L., Shulman, L.M., Stuart, B., Beardsley, R., & Brown, C. (2015). Relationships between antiparkinson medication nonadherence, regimen modifications, and healthcare utilization and expenditures. Parkinsonism Relat. Disord., 21 (1). 36-41. DOI: https://doi.org/10.1016/j.parkreldis.2014.10.021
Mantri, S., Fullard, M.E., Beck, J., & Willis, A.W. (2019). State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease. NPJ Parkinson’s Dis., 51, 1. DOI: https://doi.org/10.1038/s41531-019-0074-8
Kowal, S.L., Dall, T.M., Chakrabarti, R., & Jain, A. (2013). The current and projected economic burden of Parkinson’s disease in the United States. Mov. Disord., 28 (3), 311-318. DOI: https://doi.org/10.1002/mds.25292
Vivancos-Matellano, F., Garcia-Ruiz, A.J., & Garcia-Agua, N. (2016). Soler Pharmacoeconomic study of the treatment of advanced Parkinson’s disease. Rev. Neurol., 63 (12), 529-536.
Wang, A.S., & Gunzler, S.A. (2019). Systematic review of the pharmacoeconomics of Parkinson disease medications. Expert Opin. Pharmacother, 20 (13), 1659-1670. DOI: https://doi.org/10.1080/14656566.2019.1622091
Wong, S.L., Gilmour, H., & Ramage-Morin, P.L. (2014). Parkinsons disease: Prevalence, diagnosis and impact. Health Rep., 25 (11), 10-14.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
